ArticleClinical parkinsonism & related disorders2026
Clopidogrel use is associated with an increased prevalence of Parkinson's disease, particularly among US adults with diabetes.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antiplatelet drugs have been hypothesized to be involved in the pathological process of Parkinson's disease (PD) by affecting neuroinflammation and vascular function. However, their association with PD prevalence at the population level remains unclear. This study aimed to investigate the relationship between antiplatelet drug use and PD prevalence among American adults. Methods: This cross-sectional study included 21,288 participants aged 40 years and older from the 1999-2018 National Health and Nutrition Examination Survey (NHANES). Antiplatelet drug use was assessed through prescription records, and PD diagnosis was based on the use of typical anti-PD medications. The association between antiplatelet drug use and PD prevalence was analyzed using weighted multivariate logistic regression models. Results: After adjusting for multiple confounders, antiplatelet drug use was associated with a higher prevalence of PD (OR = 1.66, 95% CI: 1.08-2.56). Specifically, clopidogrel use was significantly associated with increased prevalence (OR = 1.75, 95% CI: 1.01-3.01), whereas aspirin showed no significant association. Stratified and interaction analyses further revealed that the association with clopidogrel was statistically significant only in diabetic patients (OR = 3.80, 95% CI: 1.68-8.60), whereas no significant association was observed in non-diabetic patients. Conclusion: Antiplatelet drug use, particularly clopidogrel, is associated with increased PD prevalence, with this association being particularly pronounced in diabetic patients. However, as a cross-sectional analysis, this study cannot infer causality; furthermore, the medication-based definition of PD may involve diagnostic misclassification. Therefore, these findings should be interpreted with caution. Consideration could be given to enhanced monitoring of neurological symptoms for diabetic patients on long-term clopidogrel therapy. Prospective studies are needed to further explore potential mechanisms and temporal relationships.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.